Bioventus Inc (BVS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating
CCORF Maintains Bioventus(BVS.US) With Buy Rating, Maintains Target Price $12
Express News | Bioventus Inc - Divestiture Reduces Annual Revenue by $50 Million and Adjusted Ebitda by $6 Million
Express News | Bioventus Inc - Expects to Net $20 Million After Fees and Expenses
Express News | Bioventus Inc - Transaction Includes $45 Million Total Cash Consideration
Bioventus Announces Divestiture of Its Advanced Rehabilitation Business to Accelmed Partners
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating, Raises Target Price to $17
Craig-Hallum Maintains Buy on Bioventus, Raises Price Target to $17
Analysts Are Bullish on These Healthcare Stocks: Bioventus (BVS), Sight Sciences (SGHT)
Zacks.com Featured Highlights Include Bioventus, Great Lakes Dredge & Dock and AxoGen
Bioventus Surges 103% in Six Months: Is the Stock Worth a Buy?
Small-cap Stocks Have Climbed Recently. Here Are the Ones Most Poised for Further Upside
Bull Of The Day: Bioventus (BVS)
Bioventus and Pool Have Been Highlighted as Zacks Bull and Bear of the Day
Executives Buying W. P. Carey And 2 Other Stocks
Bioventus Is Maintained at Buy by Canaccord Genuity
CCORF Maintains Bioventus(BVS.US) With Buy Rating, Raises Target Price to $12
CCORF analyst William Plovanic maintains $Bioventus(BVS.US)$ with a buy rating, and adjusts the target price from $7 to $12.According to TipRanks data, the analyst has a success rate of 40.5% and a
Express News | Bioventus Inc : Canaccord Genuity Raises Target Price to $12 From $8
Earnings Call Summary | Bioventus(BVS.US) Q2 2024 Earnings Conference